[go: up one dir, main page]

CL2003002287A1 - COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS - Google Patents

COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS

Info

Publication number
CL2003002287A1
CL2003002287A1 CL200302287A CL2003002287A CL2003002287A1 CL 2003002287 A1 CL2003002287 A1 CL 2003002287A1 CL 200302287 A CL200302287 A CL 200302287A CL 2003002287 A CL2003002287 A CL 2003002287A CL 2003002287 A1 CL2003002287 A1 CL 2003002287A1
Authority
CL
Chile
Prior art keywords
piridina
compounds
tieneo
carbonitrils
carbonitrilos
Prior art date
Application number
CL200302287A
Other languages
English (en)
Inventor
Diane Haris Zhang Na Boschelli
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2003002287A1 publication Critical patent/CL2003002287A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200302287A 2002-11-25 2003-11-07 COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS CL2003002287A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42886202P 2002-11-25 2002-11-25

Publications (1)

Publication Number Publication Date
CL2003002287A1 true CL2003002287A1 (es) 2005-01-14

Family

ID=32393469

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200302287A CL2003002287A1 (es) 2002-11-25 2003-11-07 COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS

Country Status (20)

Country Link
US (1) US6987116B2 (es)
EP (1) EP1565474A2 (es)
JP (1) JP2006509760A (es)
KR (1) KR20050086770A (es)
CN (1) CN1714092A (es)
AR (1) AR042087A1 (es)
AU (1) AU2003290802A1 (es)
BR (1) BR0316534A (es)
CA (1) CA2502614A1 (es)
CL (1) CL2003002287A1 (es)
EC (1) ECSP055802A (es)
MX (1) MXPA05004744A (es)
NI (1) NI200500089A (es)
NO (1) NO20051928L (es)
NZ (1) NZ540104A (es)
RU (1) RU2005120018A (es)
TW (1) TW200412950A (es)
UA (1) UA81000C2 (es)
WO (1) WO2004048386A2 (es)
ZA (1) ZA200504238B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
MX2007001216A (es) 2004-07-30 2007-03-23 Methylgene Inc Inhibidores de la senalizacion del receptor del factor de crecimiento endotelial vascular y del receptor del factor de crecimiento del hepatocito.
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CA2608726C (en) * 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
TW200806675A (en) * 2006-01-30 2008-02-01 Array Biopharma Inc Heterobicyclic thiophene compounds and methods of use
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2007089716A2 (en) * 2006-02-01 2007-08-09 The Regents Of The University Of California Use of aminopyrimidine compounds in the treatment of immune disorders
CA2636736A1 (en) * 2006-02-08 2007-08-16 Wyeth Preparation of 7-alkenyl-3 quinolinecarbonitriles via a palladium mediated coupling reaction
WO2007146824A2 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
CA2660963A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
CA2660546A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
TW200821318A (en) * 2006-09-26 2008-05-16 Wyeth Corp Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
RU2346947C1 (ru) * 2007-08-13 2009-02-20 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУВПО "КубГТУ") Способ получения фурилгетарилметанов, содержащих тиено[2,3-b]пиридиновый фрагмент
CA2697795C (en) 2007-08-29 2016-08-16 Methylgene Inc. Thieno[3,2,b]pyridinyl compounds as inhibitors of protein tyrosine kinase activity
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
EP2240494B1 (en) * 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
CN102161663B (zh) * 2008-03-05 2014-03-19 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
GB0811304D0 (en) * 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
WO2010003025A1 (en) * 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
PT2945939T (pt) 2013-01-15 2020-06-08 Incyte Holdings Corp Compostos tiazole e piridina carboxamidas úteis como inibidores das quinases pim
KR101468207B1 (ko) * 2013-02-14 2014-12-01 한국화학연구원 신규한 싸이에노[3,2-b]피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3924049A1 (en) 2019-02-13 2021-12-22 PTC Therapeutics, Inc. Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
EP3929185A4 (en) * 2019-02-19 2023-02-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. CONDENSED CYCLIC COMPOUND CONTAINING NITROGEN, METHOD FOR PREPARATION AND USE
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor
WO2021057256A1 (zh) * 2019-09-29 2021-04-01 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
US20240051968A1 (en) * 2021-02-05 2024-02-15 Ptc Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
EP4483954A1 (en) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45A (en) * 1836-10-11 Machine fob shelling cokm
EP0126970A3 (en) 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytic and anti-depressant thienopyridine derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
KR100446363B1 (ko) * 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
EP1950201A1 (en) * 1998-09-29 2008-07-30 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
DE60009888T2 (de) * 1999-04-21 2005-04-21 Wyeth Corp Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
CN1262541C (zh) * 1999-12-29 2006-07-05 惠氏公司 三环蛋白激酶抑制剂
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
PT1287001E (pt) * 2000-06-06 2004-12-31 Pfizer Prod Inc Derivados de tiofeno uteis como agentes anticancerigenos
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
EP1337513A1 (en) * 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
EP1418917A1 (en) 2001-08-10 2004-05-19 Novartis AG Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Also Published As

Publication number Publication date
RU2005120018A (ru) 2006-05-10
WO2004048386A9 (en) 2005-07-14
EP1565474A2 (en) 2005-08-24
BR0316534A (pt) 2005-10-04
TW200412950A (en) 2004-08-01
NO20051928L (no) 2005-08-19
NI200500089A (es) 2006-01-11
NZ540104A (en) 2007-05-31
US20040138251A1 (en) 2004-07-15
NO20051928D0 (no) 2005-04-20
WO2004048386A3 (en) 2004-10-07
MXPA05004744A (es) 2005-08-03
AU2003290802A1 (en) 2004-06-18
JP2006509760A (ja) 2006-03-23
AR042087A1 (es) 2005-06-08
UA81000C2 (en) 2007-11-26
US6987116B2 (en) 2006-01-17
CN1714092A (zh) 2005-12-28
WO2004048386A2 (en) 2004-06-10
KR20050086770A (ko) 2005-08-30
ECSP055802A (es) 2005-08-11
ZA200504238B (en) 2009-09-30
CA2502614A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
CL2003002287A1 (es) COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
CL2004000889A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
HUP0303271A3 (en) Use of rapamycin for preparation of pharmaceutical composition suitable for cancer treatment
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
ZA200409862B (en) Benzofused heteroaryl derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
IL174647A (en) Pyrazolopyridines and analogs thereof, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CL2007002733A1 (es) Compuestos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de obtencion de los compuestos; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, osteoporosis y cancer.
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
HUP0401718A3 (en) Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0400203A3 (en) Use of combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases, for preparation of pharmaceutical compositions
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
ID29790A (id) PENGGUNAAN IMIDAZO(1,5-a)-PIRIDO(3,2-e)-PIRAZINON SEBAGAI OBAT
IL155263A0 (en) Pharmaceutical solutions of modafinil compounds
HUP0500330A3 (en) Heterocondensated tricyclic imidazopyridines, their use and pharmaceutical compositions containing them
SI1730147T1 (sl) Substituirane triazaspiro dekan onskespojine za zdravljenje obezitete
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
HUP0401350A3 (en) Novel imidazopyridine compounds with therapeutic effect, process for their preparation and pharmaceutical compositions containing them
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
LT1807156T (lt) Naujos farmacinės kompozicijos, naudingos nemigos gydyme
JO2550B1 (en) Pyrido [3,2-d] derivatives pyrimidine, its preparation, use therapeutically
IL175724A0 (en) Tricyclic imidazopyridine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same